ROLE OF MITOCHONDRIA IN NEURODEGENERATION OF PERIPHERAL NEUROPATHIES.
Speaker: Aránzazu Bolinches
Date: 11/04/2014 - 13h
Place: Salón de Actos CIPF
Thursday, April 10, 2014
Monday, April 7, 2014
AAVLife is a gene therapy company focused on developing treatments for rare diseases with great unmet medical need.
AAVLife is a gene therapy company focused on developing treatments for rare diseases with great unmet medical need.
AAVLife's lead indication is for Friedreich’s Ataxia Cardiomyopathy
The goal is to commence a clinical trial in 2015 to evaluate gene therapy for heart disease associated with Friedreich’s Ataxia. An observational study will be initiated in 2014 as a run-up to treating patients in a Phase I/II study.
AAVLife's lead indication is for Friedreich’s Ataxia Cardiomyopathy
The goal is to commence a clinical trial in 2015 to evaluate gene therapy for heart disease associated with Friedreich’s Ataxia. An observational study will be initiated in 2014 as a run-up to treating patients in a Phase I/II study.
Friedreich's Ataxia -- An Effective Gene Therapy In An Animal Model
Friedreich's Ataxia -- An Effective Gene Therapy In An Animal Model. Science 2.0, By News Staff | April 6th 2014
The transfer, via a viral vector, of a normal copy of the gene deficient in patients, allowed to fully and very rapidly cure the heart disease in mice.
As the central nervous system is also a target of AAV vectors, Hélène Puccio and Patrick Aubourg's teams are investigating whether a similar approach using gene therapy could be as effective for the spinal cord and cerebellum as it is for the heart.
The transfer, via a viral vector, of a normal copy of the gene deficient in patients, allowed to fully and very rapidly cure the heart disease in mice.
As the central nervous system is also a target of AAV vectors, Hélène Puccio and Patrick Aubourg's teams are investigating whether a similar approach using gene therapy could be as effective for the spinal cord and cerebellum as it is for the heart.
AAVLife aimed at advancing gene therapy for cardiomyopathy in Friedreich’s ataxia to clinic
AAVLife aimed at advancing gene therapy for cardiomyopathy in Friedreich’s ataxia to clinic. International collaboration advances gene therapy for Friedreich’s ataxia
DOWNINGTOWN, Pa., April 6, 2014 /PRNewswire-USNewswire/ — The Friedreich’s Ataxia Research Alliance (FARA) is pleased to recognize the ground-breaking gene-therapy research of FARA-funded scientist Dr. Hélène Puccio.
FARA Press Release:
International collaboration advances gene therapy for Friedreich’s ataxia; AAVLife aimed at advancing gene therapy for cardiomyopathy in Friedreich's ataxia to clinic
DOWNINGTOWN, Pa., April 6, 2014 /PRNewswire-USNewswire/ — The Friedreich’s Ataxia Research Alliance (FARA) is pleased to recognize the ground-breaking gene-therapy research of FARA-funded scientist Dr. Hélène Puccio.
FARA Press Release:
International collaboration advances gene therapy for Friedreich’s ataxia; AAVLife aimed at advancing gene therapy for cardiomyopathy in Friedreich's ataxia to clinic
Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia
Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia. Morgane Perdomini, Brahim Belbellaa, Laurent Monassier, Laurence Reutenauer, Nadia Messaddeq, Nathalie Cartier, Ronald G Crystal, Patrick Aubourg & Hélène Puccio; Nature Medicine (2014) doi:10.1038/nm.3510
KEYWORDS: Cardiac failure, conditional mouse model, adeno-associated virus rh10 vector, establish the preclinical proof of concept, FRDA cardiomyopathy.
KEYWORDS: Cardiac failure, conditional mouse model, adeno-associated virus rh10 vector, establish the preclinical proof of concept, FRDA cardiomyopathy.
Sunday, April 6, 2014
Defining the action spectrum of potential PGC-1α activators on a mitochondrial and cellular level in vivo
Defining the action spectrum of potential PGC-1α activators on a mitochondrial and cellular level in vivo. Annette Hofer, Natalie Noe, Christin Tischner, Nikolay Kladt, Veronika Lellek, Astrid Schauß and Tina Wenz; Hum. Mol. Genet. (2014) 23 (9): 2400-2415. doi: 10.1093/hmg/ddt631
Gene Expression Profiling of Mitochondrial Oxidative Phosphorylation (OXPHOS) Complex I in Friedreich Ataxia (FRDA) Patients
Gene Expression Profiling of Mitochondrial Oxidative Phosphorylation (OXPHOS) Complex I in Friedreich Ataxia (FRDA) Patients . Salehi MH, Kamalidehghan B, Houshmand M, Yong Meng G, Sadeghizadeh M, Omid Aryani, Shahriar Nafissi; PLoS ONE 9(4): e94069. doi:10.1371/journal.pone.0094069
OPEN ACCESS FULL TEXT PDF
OPEN ACCESS FULL TEXT PDF
Friday, April 4, 2014
Genetics of hereditary neurological disorders in children
Genetics of hereditary neurological disorders in children. Yue Huang, Sui Yu, Zhanhe Wu, Beisha Tang; Translational Pediatrics, Vol 3, No 2 (April 2014); doi: 10.3978/j.issn.2224-4336.2014.03.04
Review Article
FULL TEXT PDF
Review Article
FULL TEXT PDF
Frataxin Silencing Inactivates Mitochondrial Complex I in NSC34 Motoneuronal Cells and Alters Glutathione Homeostasis
Frataxin Silencing Inactivates Mitochondrial Complex I in NSC34 Motoneuronal Cells and Alters Glutathione Homeostasis. Carletti, B.; Piermarini, E.; Tozzi, G.; Travaglini, L.; Torraco, A.; Pastore, A.; Sparaco, M.; Petrillo, S.; Carrozzo, R.; Bertini, E.; Piemonte, F; International Journal of Molecular Sciences. 2014; 15(4):5789-5806.
OPEN ACCESS FULL TEXT PDF
OPEN ACCESS FULL TEXT PDF
Subscribe to:
Posts (Atom)
